AIRNA Bio

AIRNA Bio

Edit info

  • Founded: 2023
  • Location: Cambridge, MA
  • Employee range: 1-50
  • Clinical stage: RD
  • Therapy area: Alpha-1 antitrypsin deficiency
  • Drug types: RAR, GEN
  • Lead product: RESTORE+ platform
  • Funding: 10 - 100M


airna.com

linkedin.com

job board


Drug notes:

Also RD undisclosed

About:

AIRNA Bio is developing oligonucleotide-based therapeutics that mediate RNA editing for patients with rare and common diseases. AIRNA uses a unique oligonucleotide drug construct to bind to a specific RNA sequence and then attract endogenous ADAR enzymes to the RNA. ADAR enzymes can mediate the chemical transformation of a specific adenosine (A) to inosine (I), which is read as guanosine (G) when translating RNA to protein. This A-to-I edit can fix pathogenic point mutations, induce therapeutically-effective gain-of-function or loss-of-function mutations, or change protein conformation.

Jobs:

Post a job


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com